Vivo Ventures
China robot surgery specialist raises $27m
Shanghai-based surgical robot business Ronovo Surgical has raised CNY200m（USD 27m）in an extended pre-Series B round led by NRL Capital.
China artificial heart developer raises $100m
China-based medical device manufacturer Evaheart has raised a Series A of close to USD 100m led by Chinese vaccine developer Sinovac.
China's Avistone Pharmaceuticals raises $200m
Avistone Pharmaceuticals, a Beijing biotech company focused on precision oncology therapeutics has raised more than $200 million in a Series A funding round led by Vivo Capital.
Vivo, Novo back Singapore's Esco Lifesciences
Vivo Capital and Novo Holdings have led a $200 million Series A round for Esco Lifesciences, a Singapore-based manufacturer of biopharma lab equipment and medical devices.
Sequoia leads $150m Series B for China's Visen Pharma
China’s Visen Pharmaceuticals, a drug developer targeting glandular conditions such as dwarfism and growth deficiency has raised a $150 million Series B round led by Sequoia Capital China.
China biotech player Gracell raises $100m Series C
Wellington Management, OrbiMed and Morningside Ventures have led a $100 million Series C round for Gracell Biotechnologies, a China-based developer of cancer treatments.
Quan leads $80m Series A for China biotech player
Healthcare-focused VC firm Quan Capital has led an $80 million Series A round for Citrine Medicine, a Chinese biotech developer set up by Eight Roads, F-Prime Capital, and Vivo Capital.
China's Genetron trades flat after upsizing US IPO
Genetron Holdings, a Chinese company that uses DNA sequencing to support the diagnosis and treatment of cancer, traded flat on its NASDAQ debut following a larger-than-planned $256 million IPO.
PE-backed InnoCare raises $288m in Hong Kong IPO
InnoCare Pharma, a private equity-backed Chinese drug developer focused on treatments for cancer and autoimmune diseases, has raised HK$2.24 billion ($288 million) through a Hong Kong IPO.
Chinese drug developer RemeGen raises $100m
RemeGen, a Chinese drug developer, has raised a $100 million round led by Lilly Asia Ventures and Lake Bleu Capital.
China’s Genetron secures $50m Series D, seeks US IPO
Genetron Holdings, a precision oncology technology developer in China, has raised a $50 million Series D round and filed for a US IPO.
PE-backed Hansoh Pharma completes $1b Hong Kong IPO
Hansoh Pharmaceutical Group, a Chinese drug developer that counts Hillhouse Capital and Boyu Capital among its investors, has raised HK$7.86 billion ($1 billion) through a Hong Kong IPO.
Vivo raises $1.28b for China-US healthcare fund
US and China-focused healthcare investor Vivo Capital has raised $1.28 billion for its ninth private equity fund. The predecessor vehicle closed at $750 million in 2015.
Cancer drug developer Tot Biopharm files for HK IPO
Tot Biopharm, a private equity-backed Chinese cancer drug developer, has filed for a Hong Kong IPO under rules that allow for listings by pre-revenue biotech companies.
China biotech player Innocare raises $160m
China’s Loyal Valley Capital has led a $160 million funding round for Beijing Innocare, a biotechnology developer focused on immuno-oncology and autoimmune diseases.
US, China-based Terns Pharma secures $80m Series B
Vivo Capital and Orbimed have co-led an $80 million Series B funding round for US and China-based Terns Pharmaceuticals.
Vivo leads $55m round for China’s Innocare
Sino-US healthcare specialist Vivo Capital has led a $55 million round of funding for Beijing Innocare, a biopharmaceutical company that develops treatments for cancer and autoimmune diseases.
OrbiMed leads $30m round for China's Zai Lab
Zai Lab, a pharmaceutical company that licenses pre-clinical findings in the West for development into drugs in China, has received $30 million in Series C funding led by existing investor OrbiMed.
PE investors back $402m Sinovac take-private
A consortium of private equity investors has agreed to privatize US-listed Chinese biopharmaceutical player Sinovac Biotech in a deal worth $401.8 million, bringing a contentious bidding process to an end.
Qiming’s US healthcare fund backs Harvard spin-out
Qiming US Healthcare Fund, a sector specialist vehicle launched by China’s Qiming Venture Partners, has led a $10 million Series A round for Platelet BioGenesis, a Harvard University spin-out that builds human platelets from stem cells.
Vivo raises $100m for Sino-US healthcare VC fund
Healthcare specialist Vivo Capital has closed its latest Sino-US venture capital fund with around $100 million in commitments. The vehicle will focus on early-stage investments.
US PE firm leads $41m round for Japan's Takeda
US-based GP Frazier Healthcare Partners is leading a $41 million Series A round for Japanese medical research and development company Takeda Pharmaceutical.
Vivo Capital leads Series B for China’s cosmetic surgery app
Healthcare specialist Vivo Capital has led a Series B round of funding for Gengmei, a Chinese cosmetic surgery social networking app, with participation from Sequoia Capital.
Johnson & Johnson commits $15m to Vivo's healthcare fund
Johnson & Johnson Innovation (JJDC) - the venture capital arm of the eponymous healthcare and consumer goods multinational - has committed to $15 million to Vivo Capital's latest US and China-focused healthcare fund.